<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="133000">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370369</url>
  </required_header>
  <id_info>
    <org_study_id>000011</org_study_id>
    <nct_id>NCT01370369</nct_id>
  </id_info>
  <brief_title>Efficacy, Pharmacokinetics and Safety of Testosterone</brief_title>
  <official_title>A Phase 2 Open-Label, Sequential Dose Escalation Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Three Volumes (1.25, 2.50 and 3.75 mL) of Testosterone Gel 2% (FE 999303) Equivalent to 23, 46 And 70 mg of Testosterone in Hypogonadal Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study of a single and repeated application of three dose levels of
      topical testosterone in hypogonadal males with morning serum testosterone concentrations &lt;
      297 ng/dL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder Rate - the percentage of subjects whose Cmin and Cavg serum testosterone levels are between 298 and 1043 ng/dL</measure>
    <time_frame>From baseline to Day 43</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (abdomen) - PK parameters, Cmax (ng/ml), t1/2 (hr), Tmax (ng/ml), AUC0-t (ng/ml*hr), will be calculated based on plasma concentrations of testosterone after an initial single treatment (testosterone) on the abdomen</measure>
    <time_frame>Days 1, 8 and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (inner thigh) - PK parameters, Cmax (ng/ml), t1/2 (hr), Tmax (ng/ml), AUC0-t (ng/ml*hr), will be calculated based on plasma concentrations of testosterone after an initial single treatment (testosterone) on the inner thigh</measure>
    <time_frame>Days 1, 8 and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (shoulders/upper arm) - PK parameters, Cmax (ng/ml), t1/2 (hr), Tmax (ng/ml), AUC0-t (ng/ml*hr), will be calculated based on plasma concentrations of testosterone after an initial single treatment (testosterone) on shoulders/upper arm</measure>
    <time_frame>Days 1, 8 and 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters - Cmax (ng/ml), t1/2 (hr), Tmax (ng/ml), AUC0-t (ng/ml*hr), for T, Free T and DHT; derived from plasma concentration versus time profiles to determine the multiple-dose profile of study drug after 10 days of treatment to shoulder/upper arm</measure>
    <time_frame>Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>From baseline to Day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Testicular Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Single Testosterone Dose (Inner Thigh)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the inner thigh followed by a seven day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Testosterone Dose (Abdomen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the abdomen followed by a seven day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Testosterone Dose (shoulder/upper arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the shoulder/upper arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone 1.25</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received testosterone gel 2% at dose of 1.25 mL (one stroke) applied once daily for 10 consecutive days to the shoulder/upper arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone 2.50</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received testosterone gel 2% at dose of 2.50 mL (two strokes) applied once daily for 10 consecutive days to the shoulder/upper arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone 3.75</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received testosterone gel 2% at dose of 3.75 mL (three strokes) applied once daily for 10 consecutive days to the shoulder/upper arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone gel (FE 99903)</intervention_name>
    <arm_group_label>Single Testosterone Dose (Inner Thigh)</arm_group_label>
    <arm_group_label>Single Testosterone Dose (Abdomen)</arm_group_label>
    <arm_group_label>Single Testosterone Dose (shoulder/upper arm)</arm_group_label>
    <arm_group_label>Testosterone 1.25</arm_group_label>
    <arm_group_label>Testosterone 2.50</arm_group_label>
    <arm_group_label>Testosterone 3.75</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18-65

          -  History of hypogonadism

          -  In good health based on medical history, physical examination and clinical laboratory
             tests

          -  Screening morning serum testosterone ≤ 297 ng/dL

          -  One or more symptoms of testosterone deficiency (i.e. fatigue, reduced libido or
             reduced sexual functioning of non-vasculogenic or neurogenic nature)

          -  Body mass index (BMI) between 18 and 31

        Exclusion Criteria:

          -  Prostate cancer

          -  Palpable prostatic mass(es)

          -  Generalized skin irritation or significant skin disease

          -  Use of any medications that could be considered anabolic (e.g. dehydroepiandrosterone
             (DHEA)) or could interfere with androgen metabolism (e.g. spironolactone,
             finasteride, ketoconazole)

          -  Clinically significant anemia or renal dysfunction

          -  Hyperparathyroidism or uncontrolled diabetes

          -  Serum PSA Levels; ≥ 4ng/mL

          -  History of cardiovascular disease

          -  Use of estrogens, Gonadotropin-releasing hormone (GnRH) agonists/antagonist, human
             growth hormone (hGH), (within previous 12 months)

          -  Use of testosterone products (within eight months for parenteral products, or six
             weeks for other preparations)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 4, 2016</lastchanged_date>
  <firstreceived_date>June 1, 2011</firstreceived_date>
  <firstreceived_results_disposition_date>July 16, 2012</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
